Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...
Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...
Eli Lilly ( NYSE: LLY) said in April that its oral weight loss therapy, orforglipron, reached the main goals in a third Phase ...
Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. The company also recently announced a partnership with Walmart that will expand access to Zepbound ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...
The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...
Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback